Title
Herpes Simplex Virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: A randomized, placebo-controlled, cross-over trial
Date Issued
15 December 2008
Access level
open access
Resource Type
journal article
Author(s)
Baeten J.M.
Strick L.B.
Whittington W.L.H.
Sanchez J.
Coombs R.W.
Magaret A.
Wald A.
Corey L.
Celum C.
Abstract
A randomized cross-over trial of herpes simplex virus type 2 (HSV-2)-suppressive therapy (valacyclovir, 500 mg twice daily, or placebo for 8 weeks, a 2-week washout period, then the alternative therapy for 8 weeks) was conducted among 20 Peruvianwomencoinfected with HSV-2 andhumanimmunodeficiency virus type 1 (HIV-1) who were not on antiretroviral therapy. Plasma samples (obtained weekly) and endocervical swab specimens (obtained thrice weekly) were collected for HIV-1 RNA polymerase chain reaction. Plasma HIV-1 level was significantly lower during the valacyclovir arm, compared with the placebo arm (-0.26 log10 copies/mL, a 45% decrease [P<.001]), as was cervical HIV-1 level (-0.35 log10 copies/ swab, a 55% decrease [P<.001]). Suppressive HSV-2 therapy has the potential to reduce HIV-1 infectiousness and slow HIV-1 disease progression. © 2008 by the Infectious Diseases Society of America. All rights reserved.
Start page
1804
End page
1808
Volume
198
Issue
12
Language
English
OCDE Knowledge area
Virología
Enfermedades infecciosas
Epidemiología
DOI
Scopus EID
2-s2.0-56749131188
PubMed ID
Source
Journal of Infectious Diseases
ISSN of the container
00221899
Sponsor(s)
Financial support: GlaxoSmithKline (research grant R 103 to C.C.); National Institutes of Health (Centers for AIDS Research Clinical Research and Laboratory Core Grants AI-27757 to C.C. and R.W.C., research grants AI-38858 and HD-40540 to R.W.C. and R37 AI-42528 to L.C., HSV Program Project Grant AI-30731 to L.C., and K24 AI071113 to A.W.).
Potential conflicts of interest: C.C. has received research grant support from GlaxoSmith-Kline (GSK) and has served on an advisory board for GSK. J.S. has received grant support from GSK. A.W. has received grant support from GSK, Antigenics, 3M, Roche, and Vical; she has been a consultant for Novartis, PowderMed, and MediGene and a speaker for Merck Vaccines. The University of Washington Virology Division Laboratories have received grant funding from GSK and Novartis to perform herpes simplex virus serologic assays and polymerase chain reaction assays for studies funded by these companies. L.C. directs these laboratories. He receives no salary support from these grants.
Sources of information:
Directorio de Producción Científica
Scopus